Nicotine receptor partial agonists for smoking cessation
about
Tobacco smoking: Health impact, prevalence, correlates and interventionsInterventions to reduce harm from continued tobacco use.Psychosocial interventions for supporting women to stop smoking in pregnancy.Smoking and the risk of type 2 diabetes.The dual orexin receptor antagonist TCS1102 does not affect reinstatement of nicotine-seeking.Estimates of effectiveness and reach for 'return on investment' modelling of smoking cessation interventions using data from England.How do smoking cessation medicines compare with respect to their neuropsychiatric safety? A protocol for a systematic review, network meta-analysis and cost-effectiveness analysis.Tobacco Harms, Nicotine Pharmacology, and Pharmacologic Tobacco Cessation Interventions for Women.Innovative approaches to support smoking cessation for individuals with mental illness and co-occurring substance use disorders.Neuregulin signaling pathway in smoking behavior.Systematic integration of biomedical knowledge prioritizes drugs for repurposing.Effects of lorcaserin (Belviq®) on nicotine- and food-maintained responding in non-human primates.Clinical Effects of Cigarette Smoking: Epidemiologic Impact and Review of Pharmacotherapy Options.Pharmacogenetic study of seven polymorphisms in three nicotinic acetylcholine receptor subunits in smoking-cessation therapies.Minding the brain: the role of pharmacotherapy in substance-use disorder treatment.Effect of Varenicline Combined With Medical Management on Alcohol Use Disorder With Comorbid Cigarette Smoking: A Randomized Clinical Trial.Maintaining abstinence from smoking after a period of enforced abstinence - systematic review, meta-analysis and analysis of behaviour change techniques with a focus on mental health.Nicotinic acetylcholine receptors in neuropathic and inflammatory pain.Stakeholder Research Priorities for Smoking Cessation Interventions within Lung Cancer Screening Programs. An Official American Thoracic Society Research Statement.Pharmacological Management of People Living with End-Stage Chronic Obstructive Pulmonary Disease.The Corticotropin Releasing Factor Receptor 1 in Alcohol Use Disorder: Still a Valid Drug Target?Tobacco Smoking is a Medical Problem: We Ought to Treat It Like One.Smoking abstinence 1 year after acute coronary syndrome: follow-up from a randomized controlled trial of varenicline in patients admitted to hospital.The safety, effectiveness and cost-effectiveness of cytisine in achieving six-month continuous smoking abstinence in tuberculosis patients - protocol for a double-blind, placebo-controlled randomised trial.Cannabidiol reverses attentional bias to cigarette cues in a human experimental model of tobacco withdrawal.Smoking Cessation for Smokers Not Ready to Quit: Meta-analysis and Cost-effectiveness AnalysisParental nicotine replacement therapy and offspring bronchitis/bronchiolitis and asthma - a nationwide population-based cohort studyJapan Atherosclerosis Society (JAS) Guidelines for Prevention of Atherosclerotic Cardiovascular Diseases 2017Smoking cessation in pregnancy: a continuing challenge in the United States
P2860
Q33852243-A1EE93C9-1BF2-41B2-A1FF-066A6B173727Q34542475-ADA384F2-3B2E-440F-9AFC-175E2216B26BQ34551210-8BF8F3D4-4176-4592-BABE-A6CBF880947EQ34554017-53C900E9-67F0-4B9C-B056-754BCB4D3530Q36309147-E1EAE7E5-9EE7-40B1-ACA2-B725BCC8F10FQ38611922-93BC9B63-3A3E-4208-A226-2C3C615EB09FQ38720906-D0A68A39-AD9C-4946-8120-C82341641401Q39337794-B20601E7-5110-4EB3-AD4C-4990FBFAB6B4Q40102553-3E6FB4F2-BEF0-439A-8ED5-9BF53B3586C3Q41687462-0B8FA239-8C9D-493C-AC03-BE465115D867Q42255083-39545997-84E2-419F-8D8C-B171BD65D55FQ46282660-3C02F926-0D51-42A2-9C28-E1C279F40968Q47136118-23E92643-B351-4762-A8C1-644FA8749E9BQ47157570-56726721-BDBA-4C1F-BC78-1E70699D826BQ47232576-920CF347-8632-41F5-8BA6-8C01B8E5F3A7Q47275723-71E4C8BB-9FD7-4C63-9FA6-4B05CEAD64DFQ47653396-6476DEF6-68AE-4B41-B47A-B57BE1104882Q47739924-F203913D-7808-45DF-9D2D-91F58036D68BQ47865950-26A8F8C9-475F-4098-9FAD-B0E24C5912D1Q47964378-9A2B8CBA-96BD-4C68-8788-78245C93387EQ48305886-136A70E3-8E38-45A1-B14E-5107D48B5B6DQ48375335-42A62114-D47A-4C04-AEF6-4A645EA5B1AFQ51734356-2CE94EC7-F9C8-4959-B85E-4A94C4DECDAFQ52574704-F5AA7D52-BE32-4926-8FD4-79E7CC1C4124Q53282635-A50AB5FE-A498-450C-8DEF-340403896F78Q56334591-FF2742D6-718D-4B81-BD66-AE1CBAA7C9A5Q57491883-F228DE9D-CC77-4DFC-B443-C65508BC0699Q58362346-AA446B52-A390-4F92-9FEF-43D5F5BA467EQ58574184-1E6B3A3F-8AC9-411F-8D66-6F53D5F5DBBD
P2860
Nicotine receptor partial agonists for smoking cessation
description
2016 nî lūn-bûn
@nan
2016 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2016 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
name
Nicotine receptor partial agonists for smoking cessation
@ast
Nicotine receptor partial agonists for smoking cessation
@en
Nicotine receptor partial agonists for smoking cessation
@en-gb
Nicotine receptor partial agonists for smoking cessation
@nl
type
label
Nicotine receptor partial agonists for smoking cessation
@ast
Nicotine receptor partial agonists for smoking cessation
@en
Nicotine receptor partial agonists for smoking cessation
@en-gb
Nicotine receptor partial agonists for smoking cessation
@nl
prefLabel
Nicotine receptor partial agonists for smoking cessation
@ast
Nicotine receptor partial agonists for smoking cessation
@en
Nicotine receptor partial agonists for smoking cessation
@en-gb
Nicotine receptor partial agonists for smoking cessation
@nl
P2093
P2860
P31
P1476
Nicotine receptor partial agonists for smoking cessation
@en
P2093
Kate Cahill
Nicola Lindson-Hawley
Thomas R Fanshawe
P2860
P304
P356
10.1002/14651858.CD006103.PUB7
P577
2016-05-09T00:00:00Z